| Efficacy and safety of #antisenseoligonucleotide therapies targeting APoC-III in patients with severe #hypertriglyceridemia: a meta-analysis of randomized controlled trials | doi.org/10.4081/mona... | #openaccess #academicsky #medsky |

Case builds for Biogen, Stoke's Dravet syndrome drug Hopes have risen for a new treatment for severe childhood epilepsy Dravet syndrome, on the back of new data for Biogen and Stoke's zorevunersen

#Biogen #Dravetsyndrome #childhoodepilepsy #StokeTherapeutics #zorevunersen #EMPERORtrial #antisenseoligonucleotide #ASO #SCN1Agenemutation #EPNS #Developmentalencephalopathy #epilepticencephalopathy #Dravetsyndromepatients #SUDEP #paediatricneurology
pharmaphorum.com/news/case-bu...